2416595-46-3
2416595-46-3 structure
- Name: Lorigerlimab
- Chemical Name: Lorigerlimab
- CAS Number: 2416595-46-3
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
- Create Date: 2023-03-10 22:11:21
- Modify Date: 2024-04-06 14:40:39
-
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3].
| Name | Lorigerlimab |
|---|
| Description | Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Lorigerlimab (0.01 nM-1 nM) 与 Jurkat/PD-1 细胞结合并阻断 PD-L1 与细胞结合[2]。 Lorigerlimab 可以独立地参与和阻断表达一种或另一种检查点分子的细胞上的 PD-1 和 CTLA-4 (EC50: PD-1+ 细胞为 0.42 nM，CTLA-4+ 细胞为 4.8 nM, PD-1 和 CTLA-4+ 细胞为 0.013 nM)[2]。 |
| In Vivo | Lorigerlimab (75 mg/kg，静脉注射) 在食蟹猴中显示出 CTLA-4 阻断作用[2]。 Lorigerlimab (10-100 mg/kg，静脉注射，4 周) 在食蟹猴中耐受性良好，半衰期约为 7 天[2]。 Animal Model: Cynomolgus monkeys [4] Dosage: 75 mg/kg Administration: i.v. Result: Increased the Ki67+ T cell fraction, and showed T cell expansion in the spleen. |
| References |
| No Any Chemical & Physical Properties |